Received Oct 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| PPV | PNEUMO (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| TTOX | TETANUS TOXOID (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Skin sensitization; This non-serious case was reported by a consumer via call center representative and described the occurrence of skin sensitization in a 59-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Flu unspecified (Influenza vaccine) for prophylaxis, 10PN-PD-Dit (Pneumococcal vaccine) for prophylaxis and Tetanus vaccine toxoid (Tetanus vaccine) for prophylaxis. Concurrent medical conditions included hypertension, diabetes and blood cholesterol increased. Concomitant products included hydrochlorothiazide, valsartan (Valsartan), metformin hydrochloride (Metformin) and atorvastatin calcium (Atorvastatin). On an unknown date, the patient received the 1st dose of Shingrix, Influenza vaccine, Pneumococcal vaccine and Tetanus vaccine. On an unknown date, an unknown time after receiving Shingrix, Influenza vaccine, Pneumococcal vaccine and Tetanus vaccine, the patient experienced skin sensitization (Verbatim: Skin sensitization). The outcome of the skin sensitization was unknown. It was unknown if the reporter considered the skin sensitization to be related to Shingrix, Influenza vaccine and Pneumococcal vaccine. The reporter considered the skin sensitization to be not reported if related to Tetanus vaccine. It was unknown if the company considered the skin sensitization to be related to Shingrix, Influenza vaccine and Pneumococcal vaccine. The company considered the skin sensitization to be not reported if related to Tetanus vaccine. Linked case(s) involving the same patient: US2025AMR132424 Additional Information: GSK Receipt Date: 14-OCT-2025 The reporter was patient itself. The reporter mentioned that the patient had some skin sensitivity in two small areas on the body approximately 2 weeks after receiving these vaccinations. The reporter also mentioned that the sensitivity resolved prior to second dose of Shingrix. The batch number was not provided and a request for this information has been made. This case is linked with case US2025AMR132424.
Blood cholesterol increased; Diabetes; Hypertension
VALSARTAN; METFORMIN; ATORVASTATIN